1. Arntzenius AC, Kromhout D, Barth JD, Reiber JHC, Bruschke AVG, Buis B, Gent CM Van, Kem-pen-Voogd N, Strikwerda S, Velde EA Van der (1985) Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden intervention trial. New Engl J Med 312:805–811
2. Berndt J, Ganmert R, Still J (1978) Mode of action of the lipid lowering agents, Clofibrate and BM 15075, on cholesterol biosynthesis in rat liver. Atherosclerosis 30:147–152
3. Klose G, Behrendt J, Vollmar J, Greten H (1979) Effect of bezafibrate on the activity of lipoprotein lipase and hepatic triglyceride hydrolase in healthy volunteers. In: Greten H, Lang PD, Schettler G (eds) Lipoproteins and coronary heart disease. Witzstrock, New York Baden-Baden Cologne, pp 182–184
4. Kohlmeier M, Schlierf G (1982) Mode of action of bezafibrate: a hypothesis. In: Crepaldi G, Greten H, Schettler G, Baggio G (eds) Lipoprotein metabolism and therapy of lipid disorders. Excerpta Medica, Amsterdam Oxford Princeton, pp 93–96
5. Levy RI, Brenside JF, Epstein SE, Kelsey SF, Passaniani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher ML, Friedman L, Friedewald W, Detre KM (1984) The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation 69:325–337